Category: 42518-42-3

On June 1, 2012, Li, Zhenhua; Wu, Danli; Zhong, Weihui published an article.Safety of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine The title of the article was Facile and efficient cyclization of anthranilonitrile to 2,4-dichloroquinazoline by bis(trichloromethyl) carbonate and catalytic amount triphenylphosphine oxide. And the article contained the following:

2,4-Dichloroquinazolines were synthesized by the cyclization of anthranilonitrile using bis(trichloromethyl)carbonate with the aid of catalytic amount of Ph3PO at 120 °C. This method was also applied to the synthesis of 2,4-dichlorothieno[2,3-d]pyrimidine. The plausible mechanism was presented. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Safety of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

The Article related to anthranilonitrile chloromethylcarbonate cyclization phenylphosphine oxide catalyst, aminothiophenonitrile chloromethylcarbonate cyclization phenylphosphine oxide catalyst, chloroquinazoline preparation, chlorothienopyrimidine preparation and other aspects.Safety of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 4, 2021, Xu, Qing; Alt, Carsten; Li, Zhe; Nilar, Shahul; Rademacher, Peter Michael; Yee, Calvin Wesley published a patent.Category: pyrimidines The title of the patent was Prepartion of pyrimidines as ferroportin inhibitors. And the patent contained the following:

The invention is related to a method of inhibiting iron transport mediated by ferroportin in a subject, comprising administering to the subject an effective amount of a compound I [Z= N, CR5; R5 = H, halo, alkyl; R6 = independently at each occurrence halo, OH, (un)substituted alkoxy, alkyl, etc.; or two R6 groups, taken together with the atom to which each is attached, form an (un)substituted 5- or 6-membered monocyclic heterocyclyl fused with ring B, a C4-C7 cycloalkyl fused with ring B, a Ph fused with ring B, or a 5- to 6-membered monocyclic heteroaryl fused with ring B; n = 0-3; Y = (Y1)0-1; Y1-4 = independently CH, N, NH, O, S, SH, SR6, NR6, CR6; provided that 1 or 2 of Y1-4 can be N, NR6, NH, O, SH or SR6; R1, R2 = independently H, alkyl, haloalkyl, alkoxy, and OH; R1 and R2 taken together with the atom to which each is attached form ring A; wherein A = (un)substituted C5-C6 cycloalkyl, 5- or 6-membered heterocyclyl, Ph, and 5- or 6-membered heteroaryl; R3 = H , optionally deuterated C1-C3 alkyl, hydroxyalkyl, C1-C3 alkoxyalkyl, haloalkyl, cyclopropyl, phenyl; R4 = CH2CONH2 and derivatives, cycloalkyl, alkylsulfonylalkyl, etc.; or R3NR4 = (un)substituted4- to 12-membered heterocyclyl] and their pharmaceutical salts. The invention is laos relates to methods of administering them for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries and to pharmaceutical compositions containing compounds I. Preparation of compounds I and their pharmaceutical acceptable salts is also given. Thus, II was prepared in 6 steps from 2-chloro-4-methylpyridine and diethylcarbonate using N-tert-Butyl-2-[(2-chloro-5H,6H,7H-cyclopenta[d]pyrimidin-4-yl)amino]acetamide (preparation given). II was tested in an in vitro ferroportin internalization assay (pEC50 = 7.7). The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).Category: pyrimidines

The Article related to pyrimdine cycloalkapyrimidine thienopyrimidine preparation ferroportin inhibitor, thienopyrimidine cyclopentapyrimidinyl amino acid amide preparation ferroportin inhibitor, hepcidin iron metabolism disorder cycloalkapyrimidine thienopyrimidine preparation, iron overload state thalassemia hemochromatosis treatment cycloalkapyridine thienopyrimidine preparation and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 30, 1981, Ishikawa, Fumiyoshi; Kosasayama, Akira; Yamaguchi, Hitoshi; Watanabe, Yoshifumi; Saegusa, Junji; Shibamura, Seiichi; Sakuma, Kyoko; Ashida, Shinichiro; Abiko, Yasushi published an article.SDS of cas: 42518-42-3 The title of the article was Cyclic guanidines. 14. Imidazo[1,2-a]thienopyrimidin-2-one derivatives as blood platelet aggregation inhibitors. And the article contained the following:

A series of novel 1,2,3,5-tetrahydroimidazo[1,2-a]thieno[2,3-d]-, and -[3,4-dpyrimidin-2-one derivatives were prepared and tested for the activity of inhibiting platelet aggregation in rats in vitro and ex vivo. They were prepared by the following reactions: NaBH4 reduction of 2,4-dichlorothienopyrimidines, followed by ethoxycarbonylmethylation and successive amination. Most of the compounds were found to be potent inhibitors of blood platelet aggregation. Structure-activity relationships indicated the essential contribution of the lactam structure and lipophilic substituents on the thiophene ring to the effective interaction of the compounds with a receptor site on the platelet. Among the compounds studied, 1,2,3,5,6,7,8,9-octahydro[1]benzothieno[1,2-d]imidazo[1,2-a]pyrimidin-2-one exhibited the most favorable activity. The experimental process involved the reaction of 2,4-Dichloro-5,6-dimethylthieno[2,3-d]pyrimidine(cas: 42518-42-3).SDS of cas: 42518-42-3

The Article related to cyclic guanidine, imidazothienopyrimidinone preparation blood platelet, thienopyrimidinone imidazo, pyrimidinone imidazothieno, structure blood platelet imidazothienopyrimidinone, reduction ethoxycarbonylmethylation amination dichlorothienopyrimidine and other aspects.SDS of cas: 42518-42-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia